MediciNova, Inc. 2013 Q3 Form 10-Q Summary
Business Context and Reporting Period
MediciNova, Inc. is a development-stage biopharmaceutical company focused on acquiring and developing small-molecule therapeutics for serious diseases with unmet medical needs. Its primary development programs are MN-166 for neurological disorders and MN-221 for acute exacerbations of asthma and chronic obstructive pulmonary disease. The filing covers the quarter and nine months ended September 30, 2013. The financial statements are unaudited.
Financial Performance and Position
| Metric | Three Months Ended September 30, 2013 | Nine Months Ended September 30, 2013 |
|---|---|---|
| Revenue | $0 | $3,257 |
| Research and development expense | $785,573 | $2.4 million |
| General and administrative expense | $1.5 million | $5.0 million |
| Total operating expenses | $2.2 million | $7.5 million |
| Operating loss | $2.2 million | $7.4 million |
| Net loss | $2.2 million | $7.4 million |
| Basic and diluted loss per share | $0.10 | $0.37 |
| Net cash used in operating activities | Not separately provided | $6.6 million |
Revenue was insufficient to produce meaningful margins; operating and net margins are not meaningful because revenue was effectively zero. Cash and cash equivalents were $10.7 million at September 30, 2013, compared with $4.0 million at December 31, 2012. Working capital was $9.9 million. Total assets were $26.2 million and total liabilities were $4.7 million.
The company reported no debt and no interest expense during the quarter or nine-month period. Current liabilities were $1.1 million, with an additional $1.7 million of long-term deferred revenue and a $2.0 million deferred tax liability. The accumulated deficit was $303.7 million.
Material Changes Versus Prior Comparable Period
- Third-quarter revenue declined to $0 from $83,787 in the prior-year quarter. Nine-month revenue declined to $3,257 from $768,584, primarily because the MN-221 clinical trials that generated Kissei-related service revenue were completed in 2012.
- Third-quarter research and development expense decreased to $785,573 from $872,555, while nine-month research and development expense decreased to $2.4 million from $4.2 million. Lower MN-221 spending more than offset increased MN-166 spending.
- Third-quarter general and administrative expense decreased to $1.5 million from $1.6 million. Nine-month general and administrative expense decreased slightly to $5.0 million from $5.1 million.
- Nine-month net loss improved to $7.4 million from $8.5 million, although the company remains loss-making and has no meaningful commercial revenue.
- Cash increased by $6.7 million during the first nine months, principally because $13.3 million of financing proceeds exceeded $6.6 million of operating cash use and $24,514 of investing cash use.
- The company raised capital through Aspire sales, an at-the-market program with Macquarie Capital, and a May 2013 private placement. These transactions increased common shares outstanding and created potential dilution from warrants.
Guidance, Outlook, Risks, Contingencies, and Unusual Items
Management stated that available working capital was expected to fund operations for at least the next 12 months under its current operating plan, while cautioning that actual cash usage could be higher. Management expects substantial net losses to continue for the next several years and acknowledges an ongoing need for additional financing.
- MN-166 development remained the principal research priority. The company reported ongoing clinical work in methamphetamine and opioid dependence, FDA Fast Track designation for methamphetamine dependence, and NIH-supported or NIH-funded trials involving progressive multiple sclerosis and alcohol dependence.
- Future MN-221 development was being considered based on FDA feedback received in October 2012. Spending on other candidates was expected to remain limited to activities necessary to preserve license rights or maximize value.
- On October 16, 2013, the company entered into a new Macquarie at-the-market agreement for up to $10 million of common stock. Through November 5, 2013, it had generated $51,000 of gross proceeds and $47,400 of net proceeds under the agreement.
- The Aspire common stock purchase agreement was terminated on October 17, 2013. No sales to Aspire occurred after September 30, 2013.
- The company identified potential dilution and possible share-price pressure from additional sales under the new Macquarie agreement as a new risk factor.
- Kissei deferred revenue was $1.7 million and is expected to be recognized as the remaining research services are performed, with some services expected to continue after 2014.
- No material legal proceedings were pending at September 30, 2013. Management reported no material changes in internal control over financial reporting and concluded that disclosure controls were effective at a reasonable assurance level.
- Stock-based compensation was $719,084 for the first nine months, and 8,980,204 potentially dilutive securities were excluded from diluted loss-per-share calculations because they were anti-dilutive.
Most Important Facts for Investors to Verify
- Whether $10.7 million of cash and $9.9 million of working capital are sufficient given the company’s projected clinical-development spending and continuing losses.
- The timing, probability, and funding sources for MN-166 clinical trials and the future development strategy for MN-221.
- The extent of future dilution from the $10 million Macquarie at-the-market facility, outstanding warrants, stock options, and the Series B preferred stock convertible into 2.2 million common shares.
- Whether Kissei-related deferred revenue will be recognized as expected and whether the related service obligations will require substantial additional cash expenditures.
- Future financing requirements and the risk that financing may be unavailable on acceptable terms, potentially requiring program delays, asset sales, or cessation of operations.
- The company’s reliance on product-candidate development and regulatory outcomes despite negligible current revenue and a $303.7 million accumulated deficit.